MCT8 deficiency, also called Allan-Herndon-Dudley syndrome, breaks the transporter that carries thyroid hormone into cells, and neurons depend on it almost exclusively. The result is a paradox that has made the condition hard to treat in both directions at once: the brain is starved of thyroid hormone while the rest of the body is exposed to too much of it, so affected boys have profound hypotonia and developmental delay alongside poor weight gain and a raised metabolic rate. Correcting the periphery does nothing for the brain, and the usual thyroid preparations cannot get in. This is the first approved treatment.
It is also the second consecutive week in which a first-ever approval has arrived for a disorder whose damage precedes its diagnosis. Thyroid hormone drives brain development in the womb and through infancy, so a treatment starting after a child presents with delay is already working against established injury. The inheritance is X-linked, which means families with an affected boy can have at-risk newborns identified before symptoms appear, if anyone is set up to look. Every one of these approvals converts a therapeutic question into a detection one.
Last week's edition led with the FDA approving the first gene therapy in Sanfilippo A. This is the clinical and biochemical detail behind the approach: autologous stem cells modified to overexpress the missing enzyme, engrafting as a lifelong internal source that reaches the brain in a way infused enzyme cannot. One patient, so read it as confirmation that the mechanism does what it is supposed to, not as an efficacy estimate.
An honest accounting of a drug used widely across indications it was never trialled in. The rationale is sound and the evidence is thinner than the prescribing, which is the situation in most rare diseases where something plausible exists and nothing else does. The limits section is the reason to read it.
Now that MEK inhibition exists, the difficult questions are who to treat, when to start, how long to continue and what counts as enough response to justify the toxicity. Delphi consensus is what fills the gap while trial evidence catches up with practice.
GBA1 is the most common genetic risk factor for Parkinson's disease, which makes this a question every Gaucher clinic is eventually asked. A cohort that follows patients who developed both gives something more concrete than a risk figure to offer in that conversation.
The cognitive and behavioural side of DM1 is consistently underweighted next to the muscle phenotype, despite often mattering more to families. Longitudinal evidence on the trajectory bears directly on care planning and on which endpoints a trial can reasonably use.
Prime editing writes a specified change without a double-strand break, which is the editing problem largely solved on paper. Delivery is the part that is not, and it is the section worth your time: editing efficiency measured in a cell line tells you very little about what reaches the target tissue in a patient.
Whether a programme uses AAV, ex vivo stem cells, an oligonucleotide or an editor is too often settled by what the sponsor already knows how to manufacture. Making the criteria explicit, target tissue, durability, whether a dose can ever be repeated, cost of goods, is useful to anyone assessing a pipeline from the outside.
Twice the diagnoses without sequencing anything new. The barrier to this is not technology but having somebody whose job it is to go back through old data as gene-disease knowledge changes, and almost no service funds that role. This is the figure to put in front of whoever decides.
A single-site companion to the network-wide UDN paper in Edition 06, and the more practical of the two: what was actually done for the patients whose exome came back negative, and which of those moves paid off. Pairs directly with item 09 above.
Newborn screening has been finding these children for years while management varied by centre, particularly around fasting limits, triheptanoin and what to monitor between crises. An international reference standard is overdue and will be the document services are measured against.
Counselling capacity limits how much genomic medicine a system can deliver, and it is the component nobody has costed properly. Putting a number on it is the precondition for funding it, and for the comparisons that follow about which parts of the conversation genuinely require a counsellor.
The specialist workforce cannot absorb the demand that mainstreaming creates, so results land with clinicians who were never trained to handle them. What preparation actually requires, beyond another module nobody has time to complete, is the question. Reads naturally after item 12.
Screening a donor generates questions the clinic then owns: whether a carrier donor can be used, how recipients are matched against their own carrier status, and what a donor-conceived person is told years later. Practical guidance on a setting where the testing arrived well before the policy.
A large non-European cohort, which is where the value is. Variant interpretation depends on allele frequencies and on phenotype correlations drawn from populations that have actually been sequenced, and the reference data remain heavily skewed towards European ancestry.
Panels routinely return moderate-penetrance findings whose management is far less settled than for BRCA1 and BRCA2. The gap between what a test can detect and what anyone can confidently recommend afterwards is widest exactly here.
Part of the answer is a statement about biology and part is a statement about our pipelines, which call these insertions poorly and therefore under-report them. For anyone holding a cohort of undiagnosed patients, that second part is the interesting one.
